Neuroblastoma

Titilope A. Ishola; Dai H. Chung

doi:10.1016/j.suronc.2007.09.005

Neuroblastoma

Titilope A. Ishola, Dai H. Chung

Research output: Contribution to journal › Review article › peer-review

65 Scopus citations

Abstract

Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.

Original language	English (US)
Pages (from-to)	149-156
Number of pages	8
Journal	Surgical Oncology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/j.suronc.2007.09.005
State	Published - Nov 2007
Externally published	Yes

Keywords

MYCN
Neuroblastoma
Tumor regression

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.suronc.2007.09.005

Cite this

@article{e9768e105074420498484643140ee6ac,

title = "Neuroblastoma",

abstract = "Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.",

keywords = "MYCN, Neuroblastoma, Tumor regression",

author = "Ishola, {Titilope A.} and Chung, {Dai H.}",

year = "2007",

month = nov,

doi = "10.1016/j.suronc.2007.09.005",

language = "English (US)",

volume = "16",

pages = "149--156",

journal = "Surgical Oncology",

issn = "0960-7404",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Neuroblastoma

AU - Ishola, Titilope A.

AU - Chung, Dai H.

PY - 2007/11

Y1 - 2007/11

N2 - Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.

AB - Neuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.

KW - MYCN

KW - Neuroblastoma

KW - Tumor regression

UR - http://www.scopus.com/inward/record.url?scp=36049033401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049033401&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2007.09.005

DO - 10.1016/j.suronc.2007.09.005

M3 - Review article

C2 - 17976976

AN - SCOPUS:36049033401

SN - 0960-7404

VL - 16

SP - 149

EP - 156

JO - Surgical Oncology

JF - Surgical Oncology

IS - 3

ER -

Neuroblastoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this